Key result
UFH dosing achieves therapeutic anti-Xa levels in ~67% of pediatric VA-ECMO measurements.
Why the study?
Does a weight-based population pharmacokinetic model optimize initial unfractionated heparin dosing in children undergoing venoarterial extracorporeal membrane oxygenation?
Observational (n=59)
No
Does a weight-based population pharmacokinetic model optimize initial unfractionated heparin dosing in children undergoing venoarterial extracorporeal membrane oxygenation?
Answers are grounded in this paper and cite their sources.
A population pharmacokinetic model incorporating body weight and time-varying clearance can optimize initial unfractionated heparin dosing in children on VA-ECMO.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cacqueray et al. (2025) conducted an observational in venoarterial (VA) ECMO (n=59). Unfractionated heparin (UFH) was evaluated on anti-Xa activity in the therapeutic range (0.3-0.7 IU/mL). Unfractionated heparin dosing in children undergoing VA-ECMO achieved therapeutic anti-Xa activity in 67% of measurements, with body weight and time-varying clearance explaining variability.
Synapse has enriched 10 related papers. Consider them for comparative context: